Table 4.
IVM cycle characteristics and results in patients with deficient oocyte maturation
| Deficient oocyte maturation | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient No. | Baseline serum FSH (IU/L) | Hormonal pretreatment | Days of stimulation | Maturation trigger | Serum E2 on oocyte retrieval day (ng/L) | COC | MII after IVM | D3 embryo | Embryo utilization rate | Fresh ET/FET | Result |
| 10 | 4.4 | HP-hMG 150 IU/day | 3 | No | 406 | 2 | 0 | 0 | NA | NA | No mature oocytes |
| 11 | 5.6 | HP-hMG 150 IU/day | 6 | No | U | 3 | 0 | 0 | NA | NA | No mature oocytes |
| 12 | 7.8 | HP-hMG 75 IU/day | 2 | No | 140 | 1 | 0 | 0 | NA | NA | No mature oocytes |
| 13 | 6.5 | HP-hMG 225 IU/day | 3 | No | 741 | 3 | 0 | 0 | NA | NA | No mature oocytes |
| 14 | 14.4 | No | NA | 5000 IU uhCG | 77 | 3 | 0 | 0 | NA | NA | No mature oocytes |
| 15 | 2.6 | HP-hMG 150 IU/day | 5 | No | 990 | 1 | 0 | 0 | NA | NA | No mature oocytes |
| 16 | 5.4 | HRT | NA | No | 200 | 13 | 0 | 0 | NA | NA | No mature oocytes |
| 17 | 7.3 | HP-hMG 75 IU/day | 4 | No | 126 | 18 | 2 | 0 | 0/1 | NA | 1 oocyte fertilized, poor-quality embryo |
| 18 | 6.6 | HP-hMG 75 IU/day | 3 | 0.2 mg triptorelin | U | 1 | 0 | 0 | NA | NA | No mature oocytes |
| 19 | 9.3 | HP-hMG 150 IU/day | 4 | 5000 IU uhCG | U | 10 | 0 | 0 | NA | NA | No mature oocytes |
| 20 | 11 | HP-hMG 150 IU/day | 2 | No | 205 | 0 | 0 | 0 | NA | NA | No mature oocytes |
| 21 | 5.8 | HP-hMG 150 IU/day | 3 | No | 196 | 8 | 1 | 0 | NA | NA | No fertilization |
| 22 | 6.4 | HP-hMG 225 IU/day | 3 | No | 542 | 28 | 2 | 0 | NA | NA | No fertilization |
| 23 | 6.2 | HRT | NA | No | 1295 | 9 | 1 | 0 | NA | NA | No fertilization |
| 7.2 | HP-hMG 150 IU/day | 10 | No | 1206 | 9 | 1 | 1 | 1/1 | FET (SET) | 1 D3 embryo, no survival after warming | |
| 6.7 | HP-hMG 150 IU/day | 2 | No | 680 | 16 | 1 | 0 | 0/1 | NA | 1 oocyte fertilized, poor-quality embryo | |
| 24 | 7.8 | HP-hMG 75 IU/day | 4 | No | 507 | 10 | 1 | 0 | NA | NA | No fertilization |
| 25 | 4.9 | HP-hMG 150 IU/day | 3 | No | 1152 | 9 | 0 | 0 | NA | NA | No mature oocytes |
| 26 | 4 | HP-hMG 225 IU/day | 3 | No | 988 | 10 | 2 | 0 | NA | NA | No fertilization |
| 4.7 | HP-hMG 225 IU/day | 3 | 5000 IU uhCG | 1059 | 6 | 1 | 0 | NA | NA | No fertilization | |
| 4.3 | HRT | NA | No | 238 | 38 | 9 | 0 | NA | NA | No fertilization | |
| 5 | HRT | NA | No | 243 | 30 | 7 | 0 | NA | NA | No fertilization | |
| 27 | 5.7 | No | NA | No | 53 | 7 | 2 | 0 | NA | NA | No fertilization |
| 28 | 7.2 | HP-hMG 225 IU/day | 3 | No | 298 | 13 | 2 | 0 | 0/1 | NA | 1 oocyte fertilized, poor-quality embryo |
| 6.7 | HP-hMG 225 IU/day | 3 | No | 760 | 7 | 1 | 0 | NA | NA | No fertilization | |
COC, cumulus-oocyte complexes; Embryo utilization rate, number of good-quality embryos transferred or cryopreserved divided per number of fertilized oocytes; ET, embryo transfer; E2, oestradiol; FET, frozen embryo transfer; HRT, hormone replacement therapy; HP-hMG, highly purified human menotropin; IU, international units; MII, mature oocytes; NA, not applicable; rFSH, recombinant FSH; NA, not applicable; SET, single embryo transfer; U, unknown; uhCG, urinary hCG
*Four FET (SET) cycles followed by two FET (double ET) cycles